Ozmosi | Penbutolol Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Penbutolol

Alternative Names: penbutolol, levatol
Clinical Status: Inactive
Latest Update: 2024-04-09
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRB1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Germany | Ireland | Italy | New Zealand | Portugal | Taiwan | Turkey

Approved Indications: None

Known Adverse Events: None

Company: Weill Medical College of Cornell University
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Heart Failure, Chronic|Heart Failure, Diastolic

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04757584

K76AG064428

P4

Completed

Heart Failure, Chronic|Heart Failure, Diastolic

2023-04-28

2024-10-16

Primary Endpoints|Treatments

NCT04767061

P19-000458

P4

Completed

Heart Failure, Diastolic|Heart Failure, Chronic

2022-04-28

2024-10-16

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title